Author: admin

Rhode Island Gay Men’s Chorus to Perform at GALA Festival 2024

The Rhode Island Gay Men’s Chorus will be performing at the prestigious international GALA Festival later this week – the largest LGBTQIA+ choral event in the world.

PROVIDENCE, RI – July 9, 2024 – The Rhode Island Gay Men’s Chorus (RIGMC) is excited to announce that the Chorus, under the direction of its Artistic Director, Kim Kuda, will be performing at the prestigious GALA Festival 2024 in Minneapolis, MN, on Saturday, July 13, 2024.

GALA Festival is the largest LGBTQIA+ choral event in the world.  It provides five days of performance, collaboration, connecting, and creating, with concerts, workshops, and social events throughout the five days.

RIGMC Chorus members come from different backgrounds, experiences, jobs, education and outlooks.  They represent a wide variety of cultural, ethnic, religious and political backgrounds.  In addition, they have different ages, musical tastes, choral experience and different levels of ability to sing, perform and dance.

Membership is open to members of the LGBTQIA+ family, and to allies, who can sing in the vocal ranges represented by the Chorus.

Regardless of their differences, RIGMC members are united in believing that voices can be used to uplift, educate, entertain and ultimately … transform.

RIGMC is well-versed in how music can uplift and transform. This belief has led the Chorus to be invited to perform at various events and venues in addition to their regular concert season, including invitations to perform at The American Heart Association, The Rhode Show, The Gamm Theater, Alders Bridge, Senior Citizen Homes, Pride Services at The Unitarian Church and the Pawsox.

In addition to these performances, RIGMC supports other organizations making a difference.  RIGMC does this in a number of ways, including by providing various levels of outreach, sponsorship, and support.

RIGMC also participates in a variety of social activities in the community. It maintains a strong presence at Providence Pride, performs at special public and private engagements, and provides donations to allied organizations.

For more information about the Rhode Island Gay Men’s Chorus, their upcoming performance at the GALA Festival, or how to join the Chorus, please visit rigmc.org or email: president@rigmc.org

About the Rhode Island Gay Men’s Chorus (RIGMC)

Founded in 1995 as the Providence Gay Men’s Chorus and then changed to Rhode Island Gay Men’s Chorus to represent the entire state of Rhode Island, the Rhode Island Gay Men’s Chorus is dedicated to fostering a spirit of inclusiveness and musical excellence. Through performances, community outreach, and educational initiatives, the RIGMC strives to make a positive impact on the lives of its members and the broader community.

Contact: Michael Abdallah President president@rigmc.org Rhode Island Gay Men’s Chorus https://rigmc.org Phone: 401-214-9924

Media Contact
Company Name: Rhode Island Gay Men’s Chorus
Contact Person: Michael Abdallah
Email: Send Email
Phone: 401-214-9924
Country: United States
Website: https://rigmc.org

The Knighting Investiture Ceremony: A Night of Honor and Tradition at The Swissotel Chicago

Chicago, IL, USA – July 9, 2024 – On the evening of June 22, 2024, the prestigious Swissotel in Chicago played host to an extraordinary event, A Knighting Investiture with The Royal and Sovereign House of Cappadocia, Constantine the Great and Saint Helen, and The Grand Priory of Illinois, led by Sir Dr. James Dentley, Baron of Saint James of Cappadocia and his team. The event was a resounding success, bringing together distinguished guests, honorees, and dignitaries from across the globe to celebrate a timeless tradition of honor, chivalry, and service.

A Night to Remember

The grand ballroom of the Swissotel was elegantly transformed, setting the perfect stage for an evening filled with grandeur and solemnity. The ambiance was a blend of modern sophistication and historical reverence, reflecting the essence of the Knighting Investiture. Attendees were greeted with a red-carpet media room, banners, and art which eloquently displayed members of The Royal Order and the postulants that entered the Royal House as new Knights, and Dames. The entrance, to the media room and the main ballroom set the tone for an evening that promised to be both memorable and inspiring.

Honoring Excellence and Service

The Knighting Investiture Ceremony is an esteemed event that recognizes individuals who have demonstrated exceptional service, leadership, and commitment, excelling in one or more of the 8 qualifying categories. This year’s honorees were a distinguished group of men and women from various fields, including philanthropy, arts, innovation, entrepreneurship, and public service. Each honoree was carefully selected for their outstanding contributions and unwavering dedication to making a positive impact in the world.

Ceremony Highlights

The evening commenced with the sound of a live trumpeter, and a drum roll as the Military and Royal procession began, featuring: The American Legion who conducted the U.S. flag ceremony and The National Anthem was sung by, Kenya Henry. Afterwards, The Knights and Dames and Grand Priors of The Royal Order walked down the red-carpet and acknowledged each other and the audience. Next The Royal Nobles were introduced. Barons, Baroness, Grand Marquis, Dukes, and Duchess in Royal fashion. Finally, entered The Grand Master of the Royal House of Cappadocia, H.R.H. Prince Rafael Andujar y Vilches, PH.D. The Grand Prefect, Baron Sidney Leluan took to the stage and highlighted the history and significance of the ceremony and the values The Royal Order upholds.

The pinnacle of the evening was the investiture itself, where each honoree was ceremoniously knighted. The women, dressed in ball gowns, and the men in black tux and white tie, each honoree knelt before Prince Rafael and received the accolade of knighthood, a moment met with applause and admiration from the audience. This act symbolized not only personal achievement but also a pledge to continue their noble endeavors with renewed vigor.

A Celebration of Heritage and Fellowship

Before the investiture, attendees enjoyed a sumptuous banquet, featuring a menu that celebrated Chicago’s culinary delights. The evening was further enlivened by performances from the renowned choir, The Soul Children of Chicago, led by Sir Dr. Walt Whitman. Last, but not least, the audience enjoyed beautiful selections to close the event performed by, Jazz artist, Dame Josephine Beavers, which added a touch of cultural richness to the celebration.

A Commitment to Future Generations

The Knighting Investiture Ceremony also served as a platform to announce new initiatives aimed at fostering the values of chivalry, service, and excellence among future generations, ensuring that the spirit of knighthood continues to inspire and empower future leaders.

Closing Remarks

The Knighting Investiture at The Swissotel Chicago was more than just a ceremony; it was a celebration of the enduring values that bind us together as a global community. As the evening ended, the sense of camaraderie and shared purpose among attendees was palpable, a testament to the power of tradition and the timeless appeal of the knightly virtues.

Media Contact: Denise Dentley

For more information, please contact:

Baron, Sir Dr. James Dentley III

Grand Prior of IL. And Baron of Saint James of Cappadocia

7080691-4017

jd@jd3media.com

www.myroyalorder.org

https://www.principalityofcappadocia.org

About The Knighting Investiture

The Knighting Investiture in Chicago is an annual event dedicated to recognizing individuals who have made significant contributions to society through their service, leadership, and commitment to excellence. The ceremony upholds the values of chivalry and honors those who embody these principles in their personal and professional lives.

Media Contact
Company Name: Vedette Global Media
Contact Person: Angel Tuccy
Email: Send Email
Phone: 720-257-9263
Country: United States
Website: https://vedettenews.com

Lee Knoll Managing Partner of Knoll & Company – Next Generation CPA Firm, Interviewed on the Influential Entrepreneurs Podcast Discussing Bookkeeping Strategy

Lee Knoll discusses streamlining bookkeeping strategies for business owners

Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-lee-knoll-managing-partner-of-knoll-company-next-generation-cpa-firm-discussing-bookkeeping-strategy/

Implementing an accounting system from the beginning is crucial for businesses as it sets a solid foundation for financial management and growth. Lee Knoll emphasizes the importance of having an accounting system in place right from the start, as it simplifies the process of managing finances and allows for easy scalability as the business expands. By starting with an accounting system early on, businesses can track their income, expenses, and cash flow effectively, providing valuable insights into their financial health.

Knoll mentions that starting with an accounting system at the beginning makes it much easier to implement additional components as the business grows. This approach enables businesses to gradually build upon their existing system, adding more sophisticated features and functionalities as needed. By establishing a strong accounting framework early on, businesses can streamline their financial processes, reduce errors, and ensure accurate record-keeping.

Furthermore, having an accounting system in place from the outset helps businesses avoid the pitfalls of trying to catch up on financial record-keeping later on. Knoll highlights the challenges of downloading thousands of transactions into Excel at the end of the year, emphasizing the importance of real-time data and consistent tracking. By maintaining an organized accounting system from the start, businesses can stay on top of their financial activities, make informed decisions, and plan for future growth effectively.

In conclusion, implementing an accounting system from the beginning not only simplifies financial management but also lays the groundwork for long-term success. Businesses that prioritize setting up a robust accounting system early on can benefit from improved efficiency, better financial visibility, and a solid foundation for growth and expansion.

Lee shared: “Forget the Shoebox, Let us do the books; We have the tools to simplify tax and accounting.”


Video Link: https://www.youtube.com/embed/RQKa0DAIXoE

About Lee Knoll

An experienced CPA, Lee has worked in the accounting profession for over 30 years advising clients in small businesses, estates, and trusts as well as being an Advanced QuickBooks Certified ProAdvisor, QuickBooks Online Certified, and Bill.com guru. He has advanced expertise in working with businesses in the real estate, transportation, legal industry and professional services industry.

Learn More: https://www.knollcpa.com/

License#16945

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Ibogaine By David Dardashti’s Ibogaine Therapy Revolutionized by Questineers’ SQL-Powered Patient Data Processing

Ibogaine By David Dardashti, a leading innovator in the field of ibogaine therapy, today announced a groundbreaking advancement in the optimization of his ibogaine treatment software.

Dardashti’s software has revolutionized the way patient data is analyzed by utilizing the power of SQL. Instead of manually sifting through mountains of data, healthcare providers can now simply ask the software specific questions to extract the information they need. This streamlined approach not only saves time and resources, but also allows for more accurate and efficient analysis of patient data. With Dardashti’s software, healthcare professionals can now make more informed decisions and provide better care for their patients.

This integration of technology and medical expertise has revolutionized the way ibogaine treatment plans are developed and implemented. By utilizing advanced algorithms and data analysis, healthcare professionals can now create highly personalized treatment plans that take into account a patient’s unique medical history, genetic makeup, and other relevant factors. This level of precision ensures that each individual receives the most effective and safe treatment possible, leading to better outcomes and improved patient satisfaction. Additionally, the integration allows for real-time monitoring and adjustments to the treatment plan, ensuring that patients receive the best care throughout their ibogaine therapy. Overall, this integration has raised the standard of care in ibogaine treatment and has opened up new possibilities for personalized medicine in the field of addiction treatment.

Dardashti’s software leverages the power of SQL to efficiently handle intricate mathematical operations such as multivariable calculus, differential equations, matrix operations, and engineering statistics. This allows the software to process and analyze large amounts of patient data with ease, without causing any disruptions to the underlying Python codebase. The integration of SQL enables the software to adapt dynamically to changing data sets and requirements, making it a versatile and robust tool for healthcare professionals and researchers. With SQL, Dardashti’s software is able to deliver accurate and reliable results in a timely manner, enhancing the efficiency and effectiveness of data analysis in the medical field.

“This epresents a significant leap forward in our ability to personalize ibogaine therapy,” said David Dardashti. “By harnessing the power of SQL and advanced data analytics, we can now unlock deeper insights from patient data, ultimately leading to more effective and tailored treatment outcomes.”

By applying our SQL expertise to the realm of ibogaine therapy, we have opened up new possibilities for data-driven treatment optimization. This is a testament to the power of collaboration and the potential of data to transform healthcare.

About David Dardashti

David Dardashti is a renowned figure in the field of ibogaine therapy, dedicated to advancing treatment methodologies and improving patient outcomes. His innovative approach has earned him recognition as a pioneer in the field.

Media Contact
Company Name: Ibogaine By David Dardashti
Contact Person: Cole Barressi
Email: Send Email
Country: United States
Website: www.ibogaineclinic.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ibogaine By David Dardashti\’s Ibogaine Therapy Revolutionized by Questineers\’ SQL-Powered Patient Data Processing

Crohn’s Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements by DelveInsight | AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 70+ key companies continuously working towards developing 80+ Crohn’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Crohn’s Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.

 

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

 

Some of the key takeaways from the Crohn’s Disease Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years. 

  • Crohn’s Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn’s Disease treatment 

  • Emerging Crohn’s Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years. 

  • In May 2024, In Eli Lilly and Company’s (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderate to severe Crohn’s disease, regardless of prior biologic treatment failure, experienced statistically significant and clinically meaningful improvements in various clinical and endoscopic measures after one year of treatment with mirikizumab compared to placebo.

  • In March 2024, Developed by Janssen Biotech, Stelara is a biologic therapy used to treat various conditions, such as moderate to severely active Crohn’s disease, active ulcerative colitis (UC), active psoriatic arthritis, and plaque psoriasis. It can be administered either subcutaneously or intravenously. The subcutaneous injection comes in two formulations: 45mg/0.5ml and 90mg/ml, both available in single-dose prefilled syringes.

  • In May 2023, For those with moderate to severe active Crohn’s disease who did not respond well to or were intolerant of one or more tumour necrosis factor blockers, the FDA has approved Rinvoq (upadacitinib). The first oral medicine for the management of Crohn’s disease that has received FDA approval is called Rinvoq.

 

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

 

Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight

 

Emerging Crohn’s Disease Drugs Under Different Phases of Clinical Development Include:

  • MORF 057: Morphic Therapeutic

  • OTL-104: Orchard Therapeutics

  • TP-317: Thetis Pharmaceuticals

  • AZD 7798: AstraZeneca

  • IMU 856: Immunic

  • CBP-307: Suzhou Connect Biopharmaceuticals

  • PF-06651600: Pfizer

  • Deucravacitinib: Bristol-Myers Squibb

  • E6011: Eisai Inc

  • Guselkumab: Janssen Pharmaceutical

  • Mirikizumab: Eli Lilly and Company

  • Filgotinib: Gilead Sciences

  • RHB-104: RedHill Biopharma

  • Ozanimod: Celgene Corporation

  • Brazikumab: AstraZeneca

 

Crohn’s Disease Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Crohn’s Disease Molecule Type

Crohn’s Disease Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Crohn’s Disease Pipeline Therapeutics Assessment

  • Crohn’s Disease Assessment by Product Type

  • Crohn’s Disease By Stage and Product Type

  • Crohn’s Disease Assessment by Route of Administration

  • Crohn’s Disease By Stage and Route of Administration

  • Crohn’s Disease Assessment by Molecule Type

  • Crohn’s Disease by Stage and Molecule Type

 

DelveInsight’s Crohn’s Disease Report covers around 80 + products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies

 

Some of the key companies in the Crohn’s Disease Therapeutics Market include:

Key companies developing therapies for Crohn’s Disease are – Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.

 

Crohn’s Disease Pipeline Analysis:

The Crohn’s Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.

  • Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies

 

Crohn’s Disease Pipeline Market Drivers

  • High prevalence of Crohn’s Disease, increase in Drug Development for Crohn’s treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn’s Disease Market.

 

Crohn’s Disease Pipeline Market Barriers

  • However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn’s Disease Market growth.

 

Scope of Crohn’s Disease Pipeline Drug Insight    

  • Coverage: Global

  • Key Crohn’s Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others

  • Key Crohn’s Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others

  • Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies

  • Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers 

 

Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials

 

Table of Contents 

1. Crohn’s Disease Report Introduction

2. Crohn’s Disease Executive Summary

3. Crohn’s Disease Overview

4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Crohn’s Disease Pipeline Therapeutics

6. Crohn’s Disease Late Stage Products (Phase II/III)

7. Crohn’s Disease Mid Stage Products (Phase II)

8. Crohn’s Disease Early Stage Products (Phase I)

9. Crohn’s Disease Preclinical Stage Products

10. Crohn’s Disease Therapeutics Assessment

11. Crohn’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Crohn’s Disease Key Companies

14. Crohn’s Disease Key Products

15. Crohn’s Disease Unmet Needs

16 . Crohn’s Disease Market Drivers and Barriers

17. Crohn’s Disease Future Perspectives and Conclusion

18. Crohn’s Disease Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements by DelveInsight | AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb

Healthcare IT Market to Progress Extraordinarily with a Notable 17.80% CAGR through 2031

“Skyquest Technology”
Healthcare IT Market Size, Share, Growth Analysis, By Product Type(Healthcare provider solutions, healthcare payer solutions, healthcare infrastructure systems, and others), By End User(Hospitals and clinics, diagnostic centers and imaging facilities, research institutes, and others), By Component(Hardware, Software, Service), By Region – Industry Forecast 2024-2031

Healthcare IT Market size was valued at USD 168.51 billion in 2022 and is poised to grow from USD 198.50 billion in 2023 to USD 736.09 billion by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

Growing Integration of Advanced Technologies for Better Patient Outcomes to Impact the Market Growth

The Healthcare IT market impacts nearly every domain of healthcare. Even if Healthcare IT refers to the infrastructure and technology to record, study, and share information about patients, it is more than that. It covers multiple technologies from wide healthcare record systems and portals of patients to personal applications and health devices. Ultimately the goal of IT in healthcare is to enhance patient health. Hence, the market is significantly driven by the increasing need for effective healthcare.

Download a detailed overview:

https://www.skyquestt.com/sample-request/healthcare-it-market

Artificial Intelligence can study huge quantities of data preserved by medical organizations in the form of pictures, medical claims, clinical research trials, and more and can efficiently identify insights and patterns, unlike human skills. Artificial Intelligence algorithms are trained to identify and tag the data patterns, while Natural Language Processing enables these algorithms to separate the relevant information. Deep learning helps computers to study and interpret data with external knowledge. Apart from this, AI holds major significance, assisting various fields.For the research experts, clinical trials remarkably support medical coding search & confirmation procedure, essential for trials and conclusion of studies.Healthcare payers can tailor their health plans by connecting a digital agent through conversational AI associated with personalized health services. Clinicians can also enhance and offer personalized care to patients via medical information or faster diagnosis of diseases. 

Shift Towards Genotyping and Genetic Testing to Enhance Personalized Treatments in the Market

The healthcare domain has witnessed incredible changes concerning technology. In the previous decade, personalized healthcare software improvement notably redefined physicians’ and patients’ approaches toward healthcare. With the increased need for customized care and enhanced efficiency of healthcare, advanced software development is today a game changer. AR and VR technologies are used in healthcare for training, surgical planning, and patient education. When combined with VR, AR can capably create computer-generated environments that can be witnessed by patients to prepare them for operations. Moreover, these technologies are specially designed to assist medical experts in extemporizing their skills during surgeries, improving possibilities of success. Another trend witnessed in the industry is the growing use of IoMT (Internet of Medical Things), which simply means the use of IoT in medicine. IoT blended with MedTech makes healthcare more interconnected than ever. AI in healthcare holds great promise. The accessibility of massive data, improved ML algorithms, improved development of software, and interconnection of 5G devices has strikingly expanded AI use in healthcare.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/healthcare-it-market

  • Eli Lilly and Company in June 2024, announced that Melissa Seymour will join them, as vice president (executive) of global quality and a member of the executive committee. The strategic expansion will fulfil the growing demand and help the pipeline grow, while they remain dedicated to guarantee that medicines are produced to the finest standards of quality.
  • Enovis Corporation Healthcare Technology, in May 2024,announced the introduction of a novel production building in San Daniele, Italy.Enovis formerly owned LimaCorporate S.p.A. (“Lima”), which was acquired in January 2024. The new plant will boost the regional and local Italian economy by creating more than 100 new jobs and doubling production capacity.
  • Amgen declared on June 12, 2024, that data from its broad portfolio and pipeline will be presented at the (EULAR) 2024 Congress, taking place in Vienna from June 12–15. The 27 abstracts from studies that Amgen has sponsored or partnered with show the company’s devotion to developing superior treatments that will enhance the quality of life for patients with rheumatic and inflammatory diseases.
  • Medical devices leader, Align Technology Inc. announced the launch of its AIC (Align Innovation Centre) in HITEC City, Hyderabad, the city’s IT center on March 2023. As per Align Technology, the Hyderabad AIC will be crucial to the advancement of its Align Digital Platform and the creation of several online and mobile apps for the Invisalign system.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/healthcare-it-market

Integrating the key trends in healthcare software development can help you to deliver positive patient experiences, reduce human errors, and assist your medical staff in giving optimum performance. The advanced software capabilities also help you to get a competitive edge in the healthcare domain. Right from enhanced security to operational flexibility, innovative healthcare software can make a great impact on your organization.

Related Reports:

Generative AI Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/healthcare-it-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Healthcare IT Market to Progress Extraordinarily with a Notable 17.80% CAGR through 2031

Batme And Ximer Unveil “Mirage” – The Summer Anthem Of 2024

Poland-born, Spain-based electronic music producer Batme teams up with Mumbai-born and based artist Ximer to release their highly anticipated track, “Mirage.” This energetic and positive summer anthem, filled with dynamic granulars and vibrant vox synths, is set to make waves worldwide starting today on all digital streaming platforms (DSPs).

A Collaboration Rooted in Shared Passion

The inspiration for “Mirage” stemmed from a mutual desire to create a track that both Batme and Ximer could feel deeply connected to, tapping into a genre that remains undefined yet profoundly felt by both artists. Drawing heavy influence from the legendary Flume, who pioneered this unique sound, Batme and Ximer have infused their own creative twists to craft a song that is truly one-of-a-kind.

A Year in the Making

The journey to “Mirage” began a year ago when Batme and Ximer started their collaborative efforts. Over the past three months, the duo focused intensively on perfecting the track, iterating several times to ensure every element was just right. The result is a song that encapsulates the essence of summer with its vibrant energy and positivity, devoid of audible lyrics but rich with a captivating vox synth. “Working with Ximer was incredibly creative and fast-paced. We kept pushing each other to explore new sounds and ideas until ‘Mirage’ was exactly what we envisioned. It’s a track that truly represents both of us,” says Batme.

Batme’s Unique Sound and Visual Mastery

Batme is renowned for his unique sound, characterized by innovative production techniques and a keen attention to detail. His dedication to visual artistry is also evident in the stunning visualizer for “Mirage,” which is available now on YouTube. This visualizer brings the song to life, enhancing the listening experience with captivating and dynamic visuals that reflect the track’s energy and vibe.

A Worldwide Release

“Mirage” is available worldwide from July 7, 2024, on all major DSPs. Fans of both artists can expect a track that not only stands out but also elevates their respective catalogs, which have been steadily growing on platforms like Spotify.

Looking Ahead

Fans won’t have to wait long for more music from Batme. A new collaboration with a Hungarian artist based in London is set to drop in just a few weeks, promising more innovative sounds and exciting new directions.

Media Contact
Company Name: Batme And Ximer
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.submithub.com/link/batme

Diffuse Large B-cell Lymphoma Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials by DelveInsight | Biomea Fusion, Autolus Limited, Xynomic Pharma, Hanmi Pharma, S IMV Inc. Seagen

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 70+ key companies continuously working towards developing 75+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Diffuse Large B-cell Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma Market.

 

The Diffuse Large B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Diffuse Large B-cell Lymphoma Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Diffuse Large B-cell Lymphoma treatment therapies with a considerable amount of success over the years. 

  • Diffuse Large B-cell Lymphoma companies working in the treatment market are Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others, are developing therapies for the Diffuse Large B-cell Lymphoma treatment 

  • Emerging Diffuse Large B-cell Lymphoma therapies in the different phases of clinical trials are- UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others are expected to have a significant impact on the Diffuse Large B-cell Lymphoma market in the coming years.  

  • In  June 2024, Pfizer Inc. (NYSE: PFE) reported detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) combined with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study indicated that this combination reduced the risk of death by 37% compared to a placebo combined with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891], p=0.0085). The OS benefit was consistent across all levels of CD30 expression. These results will be presented as a late-breaking abstract (LBA7005) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, alongside four-year results from the Phase 3 HD21 trial in advanced classical Hodgkin lymphoma (cHL) (LBA7000).

  • In April 2024, Roche has disclosed findings from the Phase III STARGLO trial demonstrating that its treatment Columvi (glofitamab), in combination with gemcitabine and oxaliplatin (GemOx), enhanced overall survival (OS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This multicenter, open-label, randomized study evaluated the safety and effectiveness of Columvi plus GemOx versus MabThera/Rituxan (rituximab) combined with GemOx.

  • In March 2024, GenFleet Therapeutics has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland to initiate a Phase Ib/II clinical trial combining GFH009 and BRUKINSA (zanubrutinib) for the treatment of diffuse large B cell lymphoma (DLBCL). GFH009 is a cyclin-dependent kinase 9 (CDK9) inhibitor developed by GenFleet, while BRUKINSA is a Bruton’s tyrosine kinase (BTK) inhibitor from BeiGene.

  • In Aug23, Prelude Therapeutics is doing clinical testing on PRT-2527, which is now in Phase I for Diffuse Large B-Cell Lymphoma. GlobalData estimates that a 78% phase transition success rate (PTSR) indication threshold is required for Phase I medications for diffuse large B-cell lymphoma to advance to Phase II.

 

Diffuse Large B-cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma, which is a cancer that originates in the lymphatic system. DLBCL specifically affects B-cells, a type of white blood cell crucial for the immune system. It is called “diffuse” because the cancerous B-cells grow rapidly and can spread throughout the lymphatic system and sometimes beyond.

 

Get a Free Sample PDF Report to know more about Diffuse Large B-cell Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight

 

Emerging Diffuse Large B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

  • UBX-303: Ubix Therapeutics

  • OPB-111077: Otsuka Pharmaceutical Co., Ltd

  • BMF-219: Biomea Fusion Inc

  • AUTO3: Autolus Limited

  • Abexinostat: Xynomic Pharmaceuticals, Inc.

  • Poseltinib: Hanmi Pharmaceutical

  • Maveropepimut: S IMV Inc.

  • Brentuximabvedotin: Seagen Inc.

  • Odronextamab: Zai Lab

  • Mosunetuzumab: Genentech

 

Diffuse Large B-cell Lymphoma Route of Administration

Diffuse Large B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical.

  • Molecule Type

 

Diffuse Large B-cell Lymphoma Molecule Type

Diffuse Large B-cell Lymphoma Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment

  • Diffuse Large B-cell Lymphoma Assessment by Product Type

  • Diffuse Large B-cell Lymphoma By Stage and Product Type

  • Diffuse Large B-cell Lymphoma Assessment by Route of Administration

  • Diffuse Large B-cell Lymphoma By Stage and Route of Administration

  • Diffuse Large B-cell Lymphoma Assessment by Molecule Type

  • Diffuse Large B-cell Lymphoma by Stage and Molecule Type

 

DelveInsight’s Diffuse Large B-cell Lymphoma Report covers around 75+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Diffuse Large B-cell Lymphoma product details are provided in the report. Download the Diffuse Large B-cell Lymphoma pipeline report to learn more about the emerging Diffuse Large B-cell Lymphoma therapies

 

Some of the key companies in the Diffuse Large B-cell Lymphoma Therapeutics Market include:

Key companies developing therapies for Diffuse Large B-cell Lymphoma are – AstraZeneca, Bristol-Myers Squibb, Seattle Genetics/Takeda, ADC Therapeutics, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer and others.

 

Diffuse Large B-cell Lymphoma Pipeline Analysis:

The Diffuse Large B-cell Lymphoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-cell Lymphoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-cell Lymphoma Treatment.

  • Diffuse Large B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Diffuse Large B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-cell Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Diffuse Large B-cell Lymphoma drugs and therapies

 

Diffuse Large B-cell Lymphoma Pipeline Market Drivers

  • Increasing Prevalence of DLBCL, increased research and development and CAR-T therapies are some of the important factors that are fueling the Diffuse Large B-cell Lymphoma Market.

 

Diffuse Large B-cell Lymphoma Pipeline Market Barriers

  • However, high cost of treatment, aggressive disease biology and geriatric vulnerability and other factors are creating obstacles in the Diffuse Large B-cell Lymphoma Market growth.

 

Scope of Diffuse Large B-cell Lymphoma Pipeline Drug Insight    

  • Coverage: Global

  • Key Diffuse Large B-cell Lymphoma Companies: Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others

  • Key Diffuse Large B-cell Lymphoma Therapies: UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others

  • Diffuse Large B-cell Lymphoma Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies

  • Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers 

 

Request for Sample PDF Report for Diffuse Large B-cell Lymphoma Pipeline Assessment and clinical trials

 

Table of Contents 

1. Diffuse Large B-cell Lymphoma Report Introduction

2. Diffuse Large B-cell Lymphoma Executive Summary

3. Diffuse Large B-cell Lymphoma Overview

4. Diffuse Large B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Diffuse Large B-cell Lymphoma Pipeline Therapeutics

6. Diffuse Large B-cell Lymphoma Late Stage Products (Phase II/III)

7. Diffuse Large B-cell Lymphoma Mid Stage Products (Phase II)

8. Diffuse Large B-cell Lymphoma Early Stage Products (Phase I)

9. Diffuse Large B-cell Lymphoma Preclinical Stage Products

10. Diffuse Large B-cell Lymphoma Therapeutics Assessment

11. Diffuse Large B-cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diffuse Large B-cell Lymphoma Key Companies

14. Diffuse Large B-cell Lymphoma Key Products

15. Diffuse Large B-cell Lymphoma Unmet Needs

16 . Diffuse Large B-cell Lymphoma Market Drivers and Barriers

17. Diffuse Large B-cell Lymphoma Future Perspectives and Conclusion

18. Diffuse Large B-cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Large B-cell Lymphoma Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials by DelveInsight | Biomea Fusion, Autolus Limited, Xynomic Pharma, Hanmi Pharma, S IMV Inc. Seagen

In-Vitro Diagnostics (IVD) Market to Flourish Notably with a 5.3% CAGR through 2031; Introduction of Personalized Medicine to Help Growth

“Skyquest Technology”
In-Vitro Diagnostics Market Size, Share, Growth Analysis, By Product type(Instrument & Reagent (Instruments, Reagents [By Raw Material {Antigen-antibody, Enzyme & Substrate, Primers & Probe), By Technology(Immunoassays (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence immunoassays, Immunofluorescence assays, Rapid tests), By Specimen(Blood, CSF, Urine, Blood Fluid), By Test Type(Laboratory Tests, Point-Of-Care Tests), By Region – Industry Forecast 2024-2031

In-vitro Diagnostics (IVD) Market size was valued at USD 83.50 billion in 2022 and is poised to grow from USD 87.93 billion in 2023 to USD 132.90 billion by 2031, growing at a CAGR of 5.3% during the forecast period (2024-2031).

In-Vitro Diagnostics market is undergoing an intense transformation driven by innovations and a steady commitment to improve healthcare. In the past few years, the industry experienced plenty of improvements mainly in domains like molecular diagnostics, genomics, the IVD space, and software solution levels, during the pandemic. Moreover, increased demand for superior testing techniques and the rising number of chronic patients to considerably impact in-Vitro Diagnostics.

The COVID-19 pandemic has significantly supported the improvements in the PCR (polymerase chain reaction) testing. It can quickly deliver results with the same test sample for various findings. The improvement of condition-specific tests and markers, the rising importance of companion diagnostics, and POC (point-of-care) testing with multiplexing competences are all expected to experience remarkable growth soon. Furthermore, Liquid Biopsy is one such key area that is heavily demanding the use of IVD technologies, wherein it offers a painless approach, allowing diagnosis of disease based on urine and blood samples. Mass spectrometry is yet another technique applied in the study of omics and is regarded as ‘diagnostics future’. This technology delivers femtomolar sensitivity, high-throughput, and quick testing, taking the study from molecular levels to cellular levels. These advancements cut across all the areas of application.

Download a detailed overview:

https://www.skyquestt.com/sample-request/in-vitro-diagnostics-market

Growing Trend of Point-of-Care Testing Projected to Majorly Transform Market

IVDs (in-vitro diagnostics) are vital resources in healthcare that inform nearly 70% of all medical decisions throughout the disease detection and monitoring of the patient’s overall health. Further, the advancements in genomics and IVDs are taking the diagnostics to the next level. Physicians are currently using refined assays physicians to help them screen for cancer-like severe diseases at an early stage, where symptoms do not exist, and cure rates are higher. Prognostic and predictive biomarkers are remarkably growingin prominence. With biomarkers assisting the doctors in various stages of a patient’s treatment, scientists are exploring a novel model called ‘precision medicine’, wherein doctors can select the right treatment for the right patient. Another major trend seen in the in-vitro diagnostics domain is the growth of POCT (point-of-care testing), usually performed near the patient like his home or the doctor’s clinic. POCT offers comparatively quick turnaround times and is reasonably priced. Microfluidics is another evolving technology holding the potential to address the challenges of the previously used methodologies. They are the miniaturized tools that control the fluids through reagents series. They are also regarded as lab-on-a-chip owing to their ability to incorporate multiple laboratory functions on one integrated circuit.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/in-vitro-diagnostics-market

  • In May 2024, Danaher Corporation agreed to a partnership with Johns Hopkins University. The partnership aims to develop novel techniques for diagnosing mild (TBI) Traumatic Brain Injury. Belonging to the Danaher Beacons program, the analysts at the University will leverage expertise from the Beckman Coulter Diagnostics, a subsidiary of Danaher and front-runner in clinical diagnostics, to establish correlations between clinical outcomes and a novel biomarker panel.
  • In May 2022, Becton, Dickinson and Company, a lead medical technology company, announced a novel high-throughput molecular diagnostic amalgamation test for Influenza A/B and SARS-CoV-2, the second test accessible for the BD COR™ PX/MX System is expected to be CE marked to the in-vitro diagnostics directive 98/79/EC.
  • In May 2024, bioMérieux, a leader in in-vitro diagnostics, announced the U.S. FDA 510(k) authorization of VIDAS® TBI (GFAP, UCH-L1). This is a serum-based test that supports the examination of patients with mild (mTBI) traumatic brain injury, comprising concussion. The assay incorporates a distinctive combination of the biomarkers UCH-L1* and GFAP, proteins that go in circulation after cellular injury.
  • In May 2022, Sysmex gathered evidence through collaborative research in partnership with Key Opinion Leaders (KOLs). To expand clinical applications, the company has been focusing on regulatory compliance for the common reagents and analyzers that are used with these assay kits. The company recently announced conformism to the European IVD regulation for these common analyzers and reagents.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/in-vitro-diagnostics-market

The in-vitro diagnostics market is anticipated to witness more major transformations with substantial growth by 2024. Trends like personalized medicine, POCT, digital diagnostics, machine learning& AI in diagnostics, liquid biopsy, and more hold promises for better overall patient improvement, lower cost, and transform the delivery of medical services.

Related Reports:

Quantum Computing Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/in-vitro-diagnostics-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In-Vitro Diagnostics (IVD) Market to Flourish Notably with a 5.3% CAGR through 2031; Introduction of Personalized Medicine to Help Growth

Senpex Technology Launches Intuitive New Mobile App to Provide a Streamlined Last-Mile Delivery Experience to a Wide Range of Users

San Jose, CA – July 9, 2024 – Senpex Technology, a logistics and delivery service that utilizes groundbreaking technology to provide the fastest and most efficient last-mile delivery resource for businesses, announced today the release of an updated mobile app that gives users access to its comprehensive suite of logistics services in an enhanced, user-friendly interface.

“Customers seeking last-mile logistics services in the modern marketplace have complex needs that demand a comprehensive suite of services,” says Anar Mammadov, co-founder and CEO of Senpex Technologies. “They need to be able to do much more than simply select a drop-off or pick-up. They want extra services, such as specialized vehicles or set-up upon delivery. Senpex understands that, so we are giving them a convenient and intelligent way to access those services.”

Senpex’s new app combines the insights gained from extensive customer feedback with the decades of experience the company has with developing technology to deliver an unparalleled solution to last-mile delivery needs. The app focuses on providing the three most popular logistics requests Senpex receives: last-mile, commercial moving, and nationwide. With each option, users are guided through an easy-to-navigate interface that allows them to provide an expanded list of details. No detail is overlooked by Senpex, which means every delivery, whether it is sent across town or across the country, can be processed with excellence.

“Prior to this update, our clients had to visit our website to gain access to the full suite of Senpex services,” Mammadov explains. “Now, they can gain access to an enhanced number of options via the app. If they need a larger vehicle or extra delivery helpers to facilitate large items, they can easily request it through the app. From pricing a pickup to confirming a delivery, everything can be done from wherever you are via the app.”

The new Senpex app also offers enhanced efficiency by enabling users to receive a detailed quote for the services they need before entering any personal information or establishing an account. Once an account is established, the app allows users to keep track of their “in progress,” “completed,” and “repetitive” orders with a simple tap. If issues occur, users can use the app to connect with a driver or customer support representative. 

Essentially, Senpex’s new app provides every user with their own personal shipping expert. Mammadov anticipates the app will be welcomed by B2B shippers, whose logistics needs are more complicated.

“Most businesses look to mobile services for basic deliveries, but shift to more cumbersome browser-based interfaces when things get complicated,” Mammadov shares. “With the new Senpex app, you can stay mobile for everything — no matter how complicated — and once you place a delivery order, the app keeps you continuously updated on your progress. Shippers no longer need to sit at their desks waiting for news that their delivery is complete. The Senpex app keeps them conveniently informed wherever they are, showing real-time tracking and live notifications.”

Last-mile logistics is one of the most in-demand and costly services in today’s global marketplace, with e-commerce needs driving the volume of deliveries higher on a daily basis. Senpex was established in 2017 to provide a more reliable and cost-effective solution for the growing number of businesses seeking to provide on-demand delivery. One of the keys to Senpex’s success has been leveraging the power of technology to bring heightened levels of efficiency to delivery routing, customer service, and driver management automation.

The new Senpex International app is now available for free download in all major app stores in both Android and IOS versions.

About Senpex

Senpex is an on-demand delivery platform specialized in providing last-mile logistics services via mobile apps, All-in-One Smart Portal, and Advanced Senpex API — a customized integrated delivery option that automates logistics needs and helps businesses scale businesses to new locations. Senpex’s AI-based framework enables its technology to deploy a unique set of custom parameters for each corporate client, providing personalized solutions that make shipping more affordable and convenient for businesses of all sizes.

Media Contact
Company Name: Senpex
Contact Person: Kevin Lessard
Email: Send Email
Country: United States
Website: www.senpex.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Senpex Technology Launches Intuitive New Mobile App to Provide a Streamlined Last-Mile Delivery Experience to a Wide Range of Users